FORA Capital LLC Takes $1.48 Million Position in Medpace Holdings, Inc. $MEDP

Key Points

• FORA Capital LLC has acquired a new position in Medpace Holdings, purchasing 4,841 shares valued at approximately $1.48 million.
• Medpace reported $3.10 earnings per share for Q2, exceeding expectations and generating $603.31 million in revenue, a 14.2% increase year-over-year.
• The company's stock has received a mixed response from analysts, with ratings ranging from two Buy, nine Hold, to three Sell, and an average target price set at $406.60.

FORA Capital LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 4,841 shares of the company's stock, valued at approximately $1,475,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MEDP. MML Investors Services LLC increased its position in shares of Medpace by 28.6% during the fourth quarter. MML Investors Services LLC now owns 4,164 shares of the company's stock valued at $1,383,000 after purchasing an additional 927 shares during the period. MGO One Seven LLC boosted its stake in Medpace by 25.8% during the fourth quarter. MGO One Seven LLC now owns 989 shares of the company's stock worth $329,000 after buying an additional 203 shares in the last quarter. Beacon Pointe Advisors LLC increased its holdings in Medpace by 11.5% in the 4th quarter. Beacon Pointe Advisors LLC now owns 7,608 shares of the company's stock valued at $2,528,000 after buying an additional 787 shares during the period. Northern Trust Corp increased its holdings in Medpace by 13.2% in the 4th quarter. Northern Trust Corp now owns 248,142 shares of the company's stock valued at $82,440,000 after buying an additional 28,968 shares during the period. Finally, AQR Capital Management LLC raised its stake in shares of Medpace by 31.3% in the 4th quarter. AQR Capital Management LLC now owns 480,186 shares of the company's stock valued at $159,532,000 after buying an additional 114,436 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Up 0.5%

NASDAQ:MEDP opened at $469.29 on Wednesday. The firm has a market cap of $13.18 billion, a PE ratio of 34.89, a price-to-earnings-growth ratio of 2.94 and a beta of 1.42. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $501.30. The company's 50-day moving average price is $385.60 and its two-hundred day moving average price is $336.58.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The company had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. Medpace's quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

MEDP has been the topic of several recent research reports. Truist Financial lifted their target price on shares of Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and raised their price target for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. Cowen downgraded Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. TD Cowen reissued a "sell" rating and issued a $366.00 target price (up from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Finally, William Blair restated a "market perform" rating on shares of Medpace in a research report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Reduce" and a consensus price target of $406.60.

Insider Transactions at Medpace

In other Medpace news, CFO Kevin M. Brady sold 12,000 shares of the business's stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the transaction, the chief financial officer owned 6,000 shares of the company's stock, valued at approximately $2,725,380. The trade was a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.14, for a total value of $3,376,050.00. Following the sale, the vice president owned 57,500 shares in the company, valued at $25,883,050. The trade was a 11.54% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 114,450 shares of company stock worth $51,791,251. 20.30% of the stock is owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.